Since 1976 EY Laboratories has developed new reagents for biomedical research, focusing on infectious diseases, pathogenesis and the immune system. EY was the first to introduce lectins and lectin conjugates for basic research and is the world's largest supplier of labeled lectin conjugates. By anticipating the future needs of the biomedical research community involved in research on emerging diseases, and drug resistant microorganisms and parasitic diseases, EY continues to develop reagents for application to human health, including in the developing world, home to the majority of the Earth's population. This system combines the latest advances in immunoassay technology, optics, electronics and computing and has made it possible to obtain quantitative analyte test results in seconds.
Positive results appear as a highly visible red spot.
Step Two Test card is placed into the digital analyzer and an instantaneous read-out is obtained. Several years ago through a combination of physical and chemical advances, EY introduced a simpler and faster test that has greater sensitivity and specificity at a reduced cost. The tests are exceptionally simple to perform. EY will also be introducing a digital analyzer which allows simultaneous quantitation of multiple analytes providing, multi-parameter diagnostic information in a minute or less. These revolutionary advances are only possible as the result of years of research on diagnostic reagents, the flow dynamics of different kinds of samples and other key parameters of rapid testing systems.